Radiation for Stage 4 Lung Cancer: 165 Real Stories

165 stories match lung cancer, stage 4 and radiation. 109 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed Central
OutcomeIn Memory
Jake, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient Story
OutcomeLiving With Cancer
Kelsey, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient Story
OutcomeResponding Well
Natalie, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient Story
OutcomeLiving With Cancer
Maggie, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient Story
OutcomeSetback / Progression
Clara, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged after repeat Tempus testing

Metastatic Site: Pelvis; spleen

As of February 2026, ALK-targeted therapy had improved Clara’s symptoms enough that she no longer needed a walker or cane, and upcoming scans would determine whether pelvic tumor surgery remained an option.

The Patient Story
OutcomeResponding Well
Phil, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient Story
OutcomeLiving With Cancer
Jennifer, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage IV Small Cell Lung Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Robertson, Female, 40s | Stage IV

Metastatic Site: Collar bones; shoulder blades; femur; pancreas;…

As of February 2026, Jennifer had shown no evidence of disease since August 2025 after tarlatamab-dlle and whole-brain radiation, while continuing tarlatamab infusions every other Monday and scans every 3 months.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: never-smoker with complete remission

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR20ins mutation; TP53 p.Q192 mutation; PD-L1 TPS 0%; CPS 0%

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bilateral…

The patient had a durable response to high-dose furmonertinib, later developed a right cerebellar metastasis treated with stereotactic radiation, and continued to benefit from furmonertinib as of April 2025 with 27 months of progression-free survival reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lynch-associated lung and colorectal cancers responded to immunotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: dMMR/MSI-H pattern with MLH1/PMS2 loss and germline MLH1 mutation; KRAS and PTEN mutations; PD-L1 TPS 15%.

Metastatic Site: right paraspinal metastatic lesion from lung…

After starting iparomlimab plus tuvonralimab, pleural and pelvic disease improved, intestinal wall involvement decreased further after 5 cycles, the paraspinal lung metastasis remained stable, tumor markers stayed normal, and treatment continued.

PubMed Central
OutcomeResponding Well
Jennifer, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV METex14 lung adenocarcinoma: responding well to capmatinib and SBRT

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; PD-L1 >80%. EGFR/RAS/MEK wild type; lung-origin markers present.

Metastatic Site: brain; bone (thoracic/lumbar vertebrae, right iliac…

At 24 months after diagnosis, he was alive, asymptomatic, and continuing capmatinib with no evidence of progression and excellent tolerance.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV NSCLC with brain and leptomeningeal metastases responding to radiotherapy, camrelizumab, GM-CSF, and chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung cancer markers supported adenocarcinoma. PD-L1 negative; no common lung driver found; TMB high; MSI not detected.

Metastatic Site: brain, leptomeningeal disease, left supraclavicular…

As of March 2025, leptomeningeal metastases had complete response, brain lesions had further regression, the lung lesion had decreased from 76 mm to 21 mm, and overall disease remained in partial response with 69 months of progression-free survival since radiotherapy.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IVB SMARCA4-deficient NSCLC with brain metastasis: stable disease after surgery, radiation, chemotherapy, immunotherapy, and bevacizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: SMARCA4/BRG-1 loss with TP53 and other mutations; TMB high; PD-L1 <1%; MSI-H not detected.

Metastatic Site: brain

As of October 2025, the patient had stable disease, no brain recurrence, a controlled left lower-lobe lung lesion, and manageable treatment toxicity while continuing bevacizumab plus pemetrexed maintenance.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Synchronous primary squamous lung cancers: long disease control after multimodal therapy, then Stage IVA lung recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Squamous lung cancers with PD-L1 20% and no driver mutation detected; P40/P63 markers supported squamous type.

Metastatic Site: bilateral lung metastases at recurrence

As of November 2025, the patient had achieved 72 months of progression-free survival and remained alive at 75 months, but had developed Stage IVA recurrent pulmonary squamous cell carcinoma with bilateral lung metastases and had restarted systemic therapy.

PubMed Central
OutcomeSetback / Progression
Drea, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ROS1 Non-Small Cell Lung Cancer: Drea's Patient Story

Patient Info: Drea, Female, Under 40 | Stage IV

Biomarkers: ROS1-positive

Metastatic Site: bilateral lungs; spine; pelvis; brain

Drea had about 3 years of good response and quality of life on her first ROS1 TKI; after new lesions appeared, a second TKI was keeping disease under control with manageable symptoms.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma: fatal hemoptysis from pulmonary artery pseudoaneurysm after chemoradiotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CEA 62 ng/mL; CA19-9 and neuron-specific enolase within normal limits; no molecular biomarkers reported

Metastatic Site: bone (11th thoracic vertebra)

The patient died from airway obstruction after massive hemoptysis caused by rupture of a pulmonary artery pseudoaneurysm that developed at the tumor-invaded pulmonary artery site after chemoradiotherapy.

PubMed Central
OutcomeIn Memory